- Home
- MTVA vs LPCN Comparison
MTVA vs LPCN Comparison
Compare MTVA & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- LPCN
- Stock Information
- Founded
- MTVA 2014
- LPCN 1997
- Country
- MTVA United States
- LPCN United States
- Employees
- MTVA N/A
- LPCN N/A
- Industry
- MTVA
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- MTVA
- LPCN Health Care
- Exchange
- MTVA NYSE
- LPCN Nasdaq
- Market Cap
- MTVA 14.3M
- LPCN 16.1M
- IPO Year
- MTVA N/A
- LPCN N/A
- Fundamental
- Price
- MTVA $0.71
- LPCN $3.44
- Analyst Decision
- MTVA Strong Buy
- LPCN Strong Buy
- Analyst Count
- MTVA 2
- LPCN 2
- Target Price
- MTVA $7.50
- LPCN $9.00
- AVG Volume (30 Days)
- MTVA 64.8K
- LPCN 41.8K
- Earning Date
- MTVA 08-13-2025
- LPCN 08-07-2025
- Dividend Yield
- MTVA N/A
- LPCN N/A
- EPS Growth
- MTVA N/A
- LPCN N/A
- EPS
- MTVA N/A
- LPCN N/A
- Revenue
- MTVA N/A
- LPCN $3,674,834.00
- Revenue This Year
- MTVA N/A
- LPCN N/A
- Revenue Next Year
- MTVA N/A
- LPCN N/A
- P/E Ratio
- MTVA N/A
- LPCN N/A
- Revenue Growth
- MTVA N/A
- LPCN N/A
- 52 Week Low
- MTVA $0.60
- LPCN $2.68
- 52 Week High
- MTVA $4.36
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- LPCN 60.97
- Support Level
- MTVA N/A
- LPCN $3.10
- Resistance Level
- MTVA N/A
- LPCN $3.27
- Average True Range (ATR)
- MTVA 0.00
- LPCN 0.20
- MACD
- MTVA 0.00
- LPCN 0.03
- Stochastic Oscillator
- MTVA 0.00
- LPCN 73.33
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.